# Title

 Food and Drugs. PART 514â€”NEW ANIMAL DRUG APPLICATIONS


# ID

 CFR-2018-title21-vol6.Pt. 514


# Structured Analysis Summary

| Type        | Values                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|:------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Constraints | ['before', 'within', 'more than', 'no later than', 'later than', 'less than', 'after', 'at least', 'greater', 'prior to']                                                                                                                                                                                                                                                                                                                                                                   |
| Duration    | ['30.0 day', '1.0 year', '5.0 year', '180.0 day', '15.0 day', '6.0 month', '2.0 year', '60.0 day', '3 day', '3.0 day', '45.0 day', '1.0 day', '90.0 day', '15 day', '3.0 month', '25.0 day']                                                                                                                                                                                                                                                                                                |
| Condition   | ['until', 'unless', 'not subject to', 'where', 'as soon as', 'if not', 'subject to', 'provided that', 'when', 'if']                                                                                                                                                                                                                                                                                                                                                                         |
| Entities    | ['United States', 'Approval', 'Agriculture', 'Such', 'Ingredient', 'Similar', 'ANADA', 'Unexpected', 'Serious', 'Annual', 'New Animal Drugs', 'Chemical', 'Explain', 'Effectiveness', 'Rockville, MD', 'Review', 'Applicant', 'Judicial', 'Drug', 'Reasonable', 'Periodic', 'Isolated', 'Food', 'Nonapplicant', 'Dispute', 'Potential', 'Adequate', 'Evaluation', 'Experimental', 'Refusal', 'Adverse', 'English', 'Expiration', 'Appropriate', 'Surveillance', 'Include', 'New', 'Untrue'] |
| Date        | ['1975-07-01', '2018-12-31', '1913-03-04', '2301-05-01', '2018-03-31', '2018-01-01']                                                                                                                                                                                                                                                                                                                                                                                                        |


# Structured Analysis With Context

 


## Constraints

| Constraints   | Context                                                                                                                            |
|:--------------|:-----------------------------------------------------------------------------------------------------------------------------------|
| within        | not reside or have a place of business within the United States, the application must also furnish                                 |
| within        | not reside or have a place of business within the United States, the application must also furnish                                 |
| prior to      | Final printed labeling will ordinarily be required  prior to  approval of an application.                                          |
| within        | Alternative methods or variations in methods  within reasonable limits that do not affect such characteristics                     |
| within        | should be capable of determining the active components within a reasonable degree of accuracy and of assuring                      |
| at least      | of four identical, separately packaged subdivisions, each containing at least three times the amount required to perform the       |
| after         | upon cessation of treatment and at intervals there after in order to establish a disappearance curve; if                           |
| more than     | if the drug is to be used in more than one species, drug residue studies or appropriate metabolic                                  |
| after         | location so that the page numbers remain legible after the application has been bound, and organize the                            |
| after         | in folders amendments, supplements, and other correspondence sent after  submission of an original application.                    |
| after         | particular serious adverse drug event, expected or unexpected, after  appropriate adjustment for drug exposure.                    |
| greater       | labeling, but differs from the event because of greater  severity or specificity.                                                  |
| at least      | treatment, or prevention of disease must consist of at least one adequate and well-controlled study on the basis                   |
| at least      | body of an animal generally must consist of at least one adequate and well-controlled study on the basis                           |
| within        | effective for the intended use at all doses within the range suggested in the proposed labeling for                                |
| more than     | drug means a new animal drug that contains more than one active ingredient or animal drug that is                                  |
| at least      | each active ingredient or animal drug intended for at least one use that is different from all the                                 |
| more than     | For such combination new animal drugs that contain more than one antibacterial ingredient or animal drug, by substantial           |
| at least      | each active ingredient or animal drug intended for at least one use that is different from all other                               |
| prior to      | applicant is entitled to one or more conferences prior to the submission of an NADA, supplemental NADA, or                         |
| prior to      | one or more presubmission conferences at any time prior to the filing of a NADA, supplemental NADA, or                             |
| at least      | a presubmission conference must be received by FDA at least 30 calendar days in advance of the requested                           |
| at least      | The potential applicant must provide to FDA,  at least 30 calendar days before a scheduled presubmission conference,               |
| before        | provide to FDA, at least 30 calendar days before a scheduled presubmission conference, a detailed agenda, a                        |
| no later than | the memorandum to the potential applicant for review no later than 45 calendar days after the date of the                          |
| after         | for review no later than 45 calendar days after the date of the conference (iii) Requests for                                      |
| within        | memorandum, the request must be sent to FDA within 30 calendar days from the date a copy                                           |
| no later than | the potential applicant a response to their request no later than 45 calendar days after the date of receipt                       |
| after         | their request no later than 45 calendar days after  the date of receipt of the request.                                            |
| more than     | If FDA requires  more than one field study to establish by substantial evidence                                                    |
| more than     | If FDA requires  more than one field study to establish by substantial evidence                                                    |
| no later than | Such justification must be provided  no later than 25 calendar days after the date of the                                          |
| after         | be provided no later than 25 calendar days after the date of the conference at which the                                           |
| more than     | of the conference at which the requirement for more than  one field study is established.                                          |
| more than     | If FDA does not believe  more than one field study is required but the potential                                                   |
| more than     | If FDA does not believe  more than one field study is required but the potential                                                   |
| after         | or effectiveness of the new animal drug appeared after  the conference.                                                            |
| before        | if: (i) The potential applicant makes to FDA, before , during, or after the presubmission conference, any                          |
| after         | potential applicant makes to FDA, before, during, or after the presubmission conference, any untrue statement of material          |
| within        | applicant should first attempt to resolve the matter within the appropriate review division beginning with the individual(s)       |
| after         | If the dispute cannot be resolved  after such attempts, the dispute shall be evaluated and                                         |
| within        | is submitted to the application once each year within 60 days before or after the anniversary date                                 |
| before        | the application once each year within 60 days before or after the anniversary date of the application's                            |
| after         | once each year within 60 days before or after the anniversary date of the application's original approval                          |
| before        | act must assess the effects of the change before  distributing a drug made with a manufacturing change.                            |
| prior to      | of a supplement that does not require approval prior to distribution of the drug, or by notification in                            |
| prior to      | Changes requiring submission and approval of a supplement prior to distribution of the drug made using the change                  |
| prior to      | must obtain approval of a supplement from FDA prior to distribution of a drug made using a change                                  |
| prior to      | submitted as a supplement requiring approval from FDA prior to distribution of the drug produced with the manufacturing            |
| at least      | Protocol.&#8221; (3) Changes requiring submission of a supplement at least 30 days prior to distribution of the drug               |
| prior to      | submission of a supplement at least 30 days prior to distribution of the drug made using the change                                |
| less than     | drug made using the change may begin not less than 30 days after receipt of the supplement by                                      |
| after         | change may begin not less than 30 days after  receipt of the supplement by FDA.                                                    |
| within        | distribute the drug made using the change if within 30 days following FDA's receipt of the supplement,                             |
| prior to      | applicant that either: (A) The change requires approval prior to distribution of the drug in accordance with paragraph             |
| within        | container closure system to another; (E) A change within the container closure system for a nonsterile drug                        |
| prior to      | requiring the submission and approval of a supplement prior to distribution of the drug made using the change                      |
| after         | prescription drug, any mailing or promotional piece used after the drug is placed on the market is                                 |
| prior to      | must obtain approval of the supplement from FDA prior to  distribution of the drug.                                                |
| prior to      | (3) Labeling changes to be placed into effect  prior to receipt of a written notice of approval of                                 |
| prior to      | in supplemental applications may be placed into effect prior to written notice of approval from FDA of a                           |
| within        | the changes made in the labeling on or within the new animal drug package no later than                                            |
| no later than | on or within the new animal drug package no later than  upon approval of the supplemental application.                             |
| after         | under section 512(e) of the act, FDA may, after due notice and opportunity for a hearing, issue                                    |
| before        | be disclosed by the Food and Drug Administration before the application has been approved, unless it has                           |
| before        | NADA file has been publicly disclosed or acknowledged before the application has been approved, no data or                         |
| after         | public, as defined in &#167;&#8201;20.81 of this chapter. after                                                                    |
| prior to      | of the following: (i) For an NADA approved prior to July 1, 1975, internal agency records that describe                            |
| after         | or internal reviews of the data and information, after deletion of: (a) Names and any information that                             |
| after         | (ii) For an NADA approved  after July 1, 1975, a summary of such data                                                              |
| prior to      | for Veterinary Medicine may at an appropriate time prior to approval of the NADA require the applicant to                          |
| within        | or study, unless it is shown to fall within the exemption established for trade secrets and confidential                           |
| after         | consumer complaints, and other similar data and information, after deletion of: (i) Names and any information that                 |
| within        | or compliance purpose and is shown to fall within  the exemption established in &#167;&#8201;20.61 of this chapter.                |
| within        | FDA District Office or local FDA resident post within 3 working days of first becoming aware that                                  |
| within        | the applicant) must submit the report to FDA within  15 working days of first receiving the information.                           |
| within        | new information, a followup report must be submitted within  15 working days of receiving such information.                        |
| within        | If additional information is sought but not obtained  within 3 months of the initial report, a followup                            |
| within        | reports of adverse drug experiences to the applicant within  3 working days of first receiving the information.                    |
| within        | should submit the report on Form FDA 1932 within  15 working days of first receiving the information.                              |
| within        | 6-month periodic drug experience reports must be submitted within 30 days following the end of the 6-month                         |
| within        | yearly periodic drug experience reports must be submitted within 90 days of the anniversary date of the                            |
| after         | date of submission or frequency of reporting, and after approval of such petition, file such reports on                            |
| at least      | reports under this section for such applications for at least 2 full years after the date of their                                 |
| after         | such applications for at least 2 full years after  the date of their initial approval.                                             |
| no later than | by or for the applicant must be submitted no later than  1 year after completion of research.                                      |
| after         | must be submitted no later than 1 year after  completion of research.                                                              |
| at least      | of serious (expected or unexpected) adverse drug events at least as often as reporting of periodic drug experience                 |
| within        | summaries must be submitted in a separate section within  the periodic drug experience report.                                     |
| more than     | under the provisions of &#167;&#8201;514.80(b)(4) with respect to more than one approved NADA or ANADA for preparations containing |
| more than     | under the provisions of &#167;&#8201;514.80(b)(4) with respect to more than one approved NADA or ANADA for preparations containing |
| before        | 1932 or Form FDA 2301, approved by FDA before  use, may be used.                                                                   |
| after         | this section for a period of 5 years after  the date of submission.                                                                |
| later than    | (d) Each report must:                                                                                                              |
|               |               (1) Be submitted not  later than March 31 each year; (2) Cover the period                                            |
| within        | under this section will be considered to fall within the exemption for confidential commercial information established in          |
| after         | comment on any apparent deficiencies in the application. after                                                                     |
| after         | be moved forward 1 day for each day after the mailing date of the request until all                                                |
| within        | If the samples are not received  within 90 days after the request, the application will                                            |
| after         | the samples are not received within 90 days after the request, the application will be considered withdrawn                        |
| within        | citing the inadequacies contained in the application, unless within 30 days the sponsor chooses to avail himself                   |
| within        | the requirements of applicable statutory provisions and regulations. within                                                        |
| after         | (a) Within 180 days  after a supplement to an approved application is filed                                                        |
| prior to      | (x) A change in the drug withdrawal period  prior to  slaughter or in the milk discard time.                                       |
| within        | not reside or maintain a place of business within the United States and the application has not                                    |
| within        | acceptable for filing, the applicant shall be notified within 30 days of receipt of the application and                            |
| within        | (a) The Commissioner shall,  within 180 days after the filing of the application,                                                  |
| after         | (a) The Commissioner shall, within 180 days  after the filing of the application, inform the applicant                             |
| before        | application, or upon the basis of other information before him with respect to a new animal drug,                                  |
| before        | application, or upon the basis of other information before him with respect to a new animal drug,                                  |
| before        | part of the application and any other information before the Food and Drug Administration with respect to                          |
| after         | cancer when ingested by man or animal or, after appropriate tests for evaluation of the safety of                                  |
| after         | regulations) in any edible portion of such animal after slaughter or in any food yielded by, or                                    |
| after         | application or not available to the Secretary until after such application was approved, or tests by new                           |
| before        | or (iii) On the basis of new information before him with respect to such drug, evaluated together                                  |
| before        | (2) That on the basis of new information before  him evaluated together with the evidence                                          |
| before        | (2) That on the basis of new information before  him evaluated together with the evidence                                          |
| within        | quality, and purity and were not made adequate within a reasonable time after receipt of written notice                            |
| after         | were not made adequate within a reasonable time after receipt of written notice from the Secretary specifying                      |
| before        | (2) That on the basis of new information before  him evaluated together with the evidence                                          |
| before        | (2) That on the basis of new information before  him evaluated together with the evidence                                          |
| within        | quality, and purity and were not made adequate within a reasonable time after receipt of written notice                            |
| after         | were not made adequate within a reasonable time after receipt of written notice from the Secretary specifying                      |
| within        | on the study conducted: (i) Placebo concurrent control. within                                                                     |
| within        | accounted for by an appropriate design, and when, within the same animal, effects due to the test                                  |
| after         | An applicant has 30 days  after  publication of the notice to request a hearing.                                                   |
| within        | If the applicant fails to request a hearing within the 30-day timeframe, the Commissioner, without further notice,                 |
| within        | a hearing in accordance with &#167;&#167;&#8201;12.20 and 12.22. within                                                            |
| after         | to request a hearing: (1) Within 30 days after publication of the notice of opportunity for hearing,                               |
| more than     | denial of approval, the hearing must not occur more than 90 days after expiration of the 30-day time                               |
| after         | hearing must not occur more than 90 days after expiration of the 30-day time period in which                                       |


## Duration

| Duration   | Context                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|:-----------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 30.0 day   | A request for a presubmission conference must be received by FDA at least 30 calendar days in advance of the requested conference date.                                                                                                                                                                                                                                                                                                              |
| 30.0 day   | The potential applicant must provide to FDA, at least 30 calendar days before a scheduled presubmission conference, a detailed agenda, a copy of any materials to be presented at the conference, a list of proposed indications and, if available, a copy of the proposed labeling for the product under consideration, and copies of materials evaluated or referenced relative to issues listed in the agenda for the conference.                 |
| 45.0 day   | FDA will send a copy of the memorandum to the potential applicant for review no later than 45 calendar days after the date of the conference                                                                                                                                                                                                                                                                                                         |
|            |               (iii) Requests for changes or clarification.                                                                                                                                                                                                                                                                                                                                                                                           |
| 30.0 day   | If a potential applicant requests changes to, or clarification of, the substance of the memorandum, the request must be sent to FDA within 30 calendar days from the date a copy of the memorandum is sent to the applicant.                                                                                                                                                                                                                         |
| 45.0 day   | If the potential applicant requests changes or clarification, FDA will send the potential applicant a response to their request no later than 45 calendar days after the date of receipt of the request.                                                                                                                                                                                                                                             |
| 25.0 day   | Such justification must be provided no later than 25 calendar days after the date of the conference at which the requirement for more than one field study is established.                                                                                                                                                                                                                                                                           |
| 60.0 day   | (iii) Minor changes and stability report (MCSR) means an annual report that is submitted to the application once each year within 60 days before or after the anniversary date of the application's original approval or on a mutually agreed upon date.                                                                                                                                                                                             |
| 30.0 day   | A comparability protocol supplement must be labeled &#8220;Prior Approval Supplement&#8212;Comparability Protocol.&#8221;                                                                                                                                                                                                                                                                                                                            |
|            |               (3) Changes requiring submission of a supplement at least 30 days prior to distribution of the drug made using the change (moderate changes).                                                                                                                                                                                                                                                                                          |
| 30.0 day   | The supplement submitted under paragraph (b)(3)(i) must be labeled &#8220;Supplement-Changes Being Effected in 30 Days.&#8221;                                                                                                                                                                                                                                                                                                                       |
|            |               (iv) Pending approval of the supplement by FDA and except as provided in paragraph (b)(3)(vi) of this section, distribution of the drug made using the change may begin not less than 30 days after receipt of the supplement by FDA.                                                                                                                                                                                                  |
| 30.0 day   | The supplement submitted under paragraph (b)(3)(i) must be labeled &#8220;Supplement-Changes Being Effected in 30 Days.&#8221;                                                                                                                                                                                                                                                                                                                       |
|            |               (iv) Pending approval of the supplement by FDA and except as provided in paragraph (b)(3)(vi) of this section, distribution of the drug made using the change may begin not less than 30 days after receipt of the supplement by FDA.                                                                                                                                                                                                  |
| 30.0 day   | (v) The applicant must not distribute the drug made using the change if within 30 days following FDA's receipt of the supplement, FDA informs the applicant that either:                                                                                                                                                                                                                                                                             |
|            |               (A) The change requires approval prior to distribution of the drug in accordance with paragraph (b)(2) of this section; or                                                                                                                                                                                                                                                                                                             |
|            |               (B) Any of the information required under paragraph (b)(3)(iv) of this section is missing.                                                                                                                                                                                                                                                                                                                                             |
| 3 day      | (b) Reporting requirements&#8212;(1) Three-day NADA/ANADA field alert report.                                                                                                                                                                                                                                                                                                                                                                        |
| 3.0 day    | The information initially may be provided by telephone or other telecommunication means, with prompt written followup using Form FDA 1932 &#8220;Veterinary Adverse Drug Reaction, Lack of Effectiveness, Product Defect Report.&#8221; The mailing cover for these reports must be plainly marked &#8220;3-Day NADA/ANADA Field Alert Report.&#8221;                                                                                                |
|            |               (2) Fifteen-day NADA/ANADA alert report&#8212;(i) Initial report.                                                                                                                                                                                                                                                                                                                                                                      |
| 15 day     | The information initially may be provided by telephone or other telecommunication means, with prompt written followup using Form FDA 1932 &#8220;Veterinary Adverse Drug Reaction, Lack of Effectiveness, Product Defect Report.&#8221; The mailing cover for these reports must be plainly marked &#8220;3-Day NADA/ANADA Field Alert Report.&#8221;                                                                                                |
|            |               (2) Fifteen-day NADA/ANADA alert report&#8212;(i) Initial report.                                                                                                                                                                                                                                                                                                                                                                      |
| 15.0 day   | The report must be submitted on Form FDA 1932, and its mailing cover must be plainly marked &#8220;15-Day NADA/ANADA Alert Report.&#8221;                                                                                                                                                                                                                                                                                                            |
|            |               (ii) Followup report.                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 15.0 day   | The applicant must promptly investigate all adverse drug events that are the subject of 15-day NADA/ANADA alert reports.                                                                                                                                                                                                                                                                                                                             |
| 15.0 day   | A followup report must be submitted on Form FDA 1932, and its mailing cover must be plainly marked &#8220;15-Day NADA/ANADA Alert Report Followup.&#8221; The followup report must state the date of the initial report and provide the additional information.                                                                                                                                                                                      |
| 3.0 month  | If additional information is sought but not obtained within 3 months of the initial report, a followup report is required describing the steps taken and why additional information was not obtained.                                                                                                                                                                                                                                                |
| 6.0 month  | This report must be accompanied by a completed Form FDA 2301 &#8220;Transmittal of Periodic Reports and Promotional Materials for New Animal Drugs.&#8221; It must be submitted every 6 months for the first 2 years following approval of an NADA or ANADA and yearly thereafter.                                                                                                                                                                   |
| 2.0 year   | This report must be accompanied by a completed Form FDA 2301 &#8220;Transmittal of Periodic Reports and Promotional Materials for New Animal Drugs.&#8221; It must be submitted every 6 months for the first 2 years following approval of an NADA or ANADA and yearly thereafter.                                                                                                                                                                   |
| 6.0 month  | The 6-month periodic drug experience reports must be submitted within 30 days following the end of the 6-month reporting period.                                                                                                                                                                                                                                                                                                                     |
| 30.0 day   | The 6-month periodic drug experience reports must be submitted within 30 days following the end of the 6-month reporting period.                                                                                                                                                                                                                                                                                                                     |
| 6.0 month  | The 6-month periodic drug experience reports must be submitted within 30 days following the end of the 6-month reporting period.                                                                                                                                                                                                                                                                                                                     |
| 90.0 day   | The yearly periodic drug experience reports must be submitted within 90 days of the anniversary date of the approval of the NADA or ANADA.                                                                                                                                                                                                                                                                                                           |
| 1.0 year   | (C) Descriptions of completed clinical trials conducted by or for the applicant must be submitted no later than 1 year after completion of research.                                                                                                                                                                                                                                                                                                 |
| 5.0 year   | The applicants and nonapplicants must maintain records and reports of all information required by this section for a period of 5 years after the date of submission.                                                                                                                                                                                                                                                                                 |
| 15.0 day   | Completed 15-day alert reports, periodic drug experience reports, and special drug experience reports must be submitted to the following address: Food and Drug Administration, Center for Veterinary Medicine, Document Control Unit (HFV-199), 7500 Standish Pl., Rockville, MD 20855-2764.                                                                                                                                                        |
| 3 day      | Three-day alert reports must be submitted to the appropriate FDA district office or local FDA resident post.                                                                                                                                                                                                                                                                                                                                         |
| 180.0 day  | The request should be made as early in the 180-day period as possible to assure timely completion.                                                                                                                                                                                                                                                                                                                                                   |
| 180.0 day  | The date used for computing the 180-day limit for the purposes of section 512(c) of the act shall be moved forward 1 day for each day after the mailing date of the request until all of the requested samples are received.                                                                                                                                                                                                                         |
| 1.0 day    | The date used for computing the 180-day limit for the purposes of section 512(c) of the act shall be moved forward 1 day for each day after the mailing date of the request until all of the requested samples are received.                                                                                                                                                                                                                         |
| 90.0 day   | If the samples are not received within 90 days after the request, the application will be considered withdrawn without prejudice.                                                                                                                                                                                                                                                                                                                    |
| 30.0 day   | (g) When an application has been found incomplete on the basis of a need for the kind of information described in &#167;&#8201;514.6, such application shall be considered withdrawn without prejudice to future filing on the date of issuance of the letter citing the inadequacies contained in the application, unless within 30 days the sponsor chooses to avail himself of the opportunity for hearing as prescribed by &#167;&#8201;514.111. |
| 180.0 day  | (a) Within 180 days after a supplement to an approved application is filed pursuant to &#167;&#8201;514.8, the Commissioner shall approve the supplemental application in accordance with procedures set forth in &#167;&#8201;514.105(a)(1) and (2) if he/she determines that the application satisfies the requirements of applicable statutory provisions and regulations.                                                                        |
| 30.0 day   | (c) If an application is determined not to be acceptable for filing, the applicant shall be notified within 30 days of receipt of the application and shall be given the reasons therefore.                                                                                                                                                                                                                                                          |
| 180.0 day  | (a) The Commissioner shall, within 180 days after the filing of the application, inform the applicant in writing of his intention to issue a notice of opportunity for a hearing on a proposal to refuse to approve the application, if the Commissioner determines upon the basis of the application, or upon the basis of other information before him with respect to a new animal drug, that:                                                    |
|            |               (1) The reports of investigations required to be submitted pursuant to section 512(b) of the act do not include adequate tests by all methods reasonably applicable to show whether or not such drug is safe for use under the conditions prescribed, recommended, or suggested in the proposed labeling thereof; or                                                                                                                   |
|            |               (2) The results of such tests show that such drug is unsafe for use under such conditions or do not show that such drug is safe for use under such conditions; or                                                                                                                                                                                                                                                                      |
|            |               (3) The methods used in and the facilities and controls used for the manufacture, processing, and packing of such drug are inadequate to preserve its identity, strength, quality, and purity; or                                                                                                                                                                                                                                      |
|            |               (4) Upon the basis of the information submitted to the Food and Drug Administration as part of the application, or upon the basis of any other information before it with respect to such drug, it has insufficient information to determine whether such drug is safe for use under such conditions.                                                                                                                                  |
| 30.0 day   | An applicant has 30 days after publication of the notice to request a hearing.                                                                                                                                                                                                                                                                                                                                                                       |
| 30.0 day   | (b) If the applicant fails to request a hearing within the 30-day timeframe, the Commissioner, without further notice, will publish a final order denying or withdrawing approval of the application.                                                                                                                                                                                                                                                |
| 30.0 day   | (c) If the applicant desires to request a hearing:                                                                                                                                                                                                                                                                                                                                                                                                   |
|            |               (1) Within 30 days after publication of the notice of opportunity for hearing, the applicant must submit to the Division of Dockets Management written objections and a request for a hearing in accordance with &#167;&#167;&#8201;12.20 and 12.22.                                                                                                                                                                                   |
| 90.0 day   | However, in the case of a denial of approval, the hearing must not occur more than 90 days after expiration of the 30-day time period in which to request a hearing, unless the presiding officer and the applicant otherwise agree; and in the case of withdrawal of approval, the hearing will occur as soon as practicable.                                                                                                                       |
| 30.0 day   | However, in the case of a denial of approval, the hearing must not occur more than 90 days after expiration of the 30-day time period in which to request a hearing, unless the presiding officer and the applicant otherwise agree; and in the case of withdrawal of approval, the hearing will occur as soon as practicable.                                                                                                                       |


## Condition

| Condition      | Context                                                                                                                                       |
|:---------------|:----------------------------------------------------------------------------------------------------------------------------------------------|
| unless         | other than the applicant may not be considered unless its use is authorized in a written statement                                            |
| if             | Each component should be ident if ied by its established name,                                                                                |
| when           | any, or complete chemical name, using structural formulas when  necessary for specific identification.                                        |
| if             | microorganism used to produce the new animal drug. if                                                                                         |
| if             | (c) Type of precursor used,  if any, to guide or enhance production of the                                                                    |
| if             | (d) Name and composition of preservative,  if  any, used in the broth.                                                                        |
| if             | the new animal drug is extracted and pur if ied.                                                                                              |
| if             | for any new animal drug, he shall: Ident if y each person who will perform any part                                                           |
| unless         | prior approval by the Food and Drug Administration, unless  permitted under &#167;&#8201;514.8.                                               |
| when           | flow sheet and indicated equations should be submitted when  needed to explain the process.                                                   |
| if             | a batch according to the formula card and, if so, at what stage and by whom it                                                                |
| if             | the drug should be given for sterility controls. if                                                                                           |
| if             | permit determination of the distribution of any batch if  its recall is required.                                                             |
| if             | marketed, including any proposed multiple dose container, and, if it is to be put into solution at                                            |
| unless         | An application may be refused  unless it includes adequate information showing that the methods                                               |
| if             | new animal drug prepared for initial marketing and, if any such sample is not from a representative                                           |
| provided that  | employed in the production of such dosage form, provided that in the case of new animal drugs marketed                                        |
| when           | following information shall be included for the samples when requested: (a) For each sample submitted, full information                       |
| if             | description of practicable methods for determining the quantity, if any, of the new animal drug in or                                         |
| if             | time, and route of administration to show levels, if any, of the drug and/or its metabolites in                                               |
| if             | time, and route of administration to show levels, if any, of the drug and/or its metabolites in                                               |
| if             | time, and route of administration to show levels, if any, of the drug and/or its metabolites in                                               |
| if             | time, and route of administration to show levels, if any, of the drug and/or its metabolites in                                               |
| where          | determined in muscle, liver, kidney, and fat and where applicable, in skin, milk, and eggs (yolk and                                          |
| where          | drug or metabolite should be determined in blood where  feasible.                                                                             |
| where          | Samples may be combined  where  necessary.                                                                                                    |
| unless         | (i) An application may be refused  unless it contains full reports of adequate tests by                                                       |
| unless         | (ii) An application may be refused  unless it includes substantial evidence of the effectiveness of                                           |
| unless         | (iii) An application may be refused  unless it contains detailed reports of the investigations, including                                     |
| unless         | (iii) An application may be refused  unless it contains detailed reports of the investigations, including                                     |
| where          | person who conducted each investigation, a statement of where  the investigations were conducted, and                                         |
| where          | person who conducted each investigation, a statement of where  the investigations were conducted, and                                         |
| if             | combination new animal drug as required in &#167;&#8201;514.4. if                                                                             |
| unless         | or animal drugs, an application may be refused unless it includes substantial evidence of the effectiveness of                                |
| if             | and address of the contract research organization, ident if ying the clinical study, and listing the obligations                              |
| if             | course of monitoring any clinical study to ver if y the accuracy of the case reports submitted                                                |
| if             | labeling which is part of this application and if the article is a prescription new animal drug,                                              |
| until          | in this application apply to the drug produced until  changes are made in conformity with &#167;&#8201;514.8.                                 |
| if             | forth in part 58 of this chapter, or, if the study was not conducted in compliance with                                                       |
| if             | all dosage forms in each application is unnecessary if reference is made to the application containing such                                   |
| if             | front cover of these submissions should be ident if ied with the name of the applicant, new                                                   |
| when           | to the Attorney General of the United States. when                                                                                            |
| if             | or hallucinogenic effect on the central nervous system, if it appears that the drug has a potential                                           |
| if             | under this definition hepatic necrosis would be unexpected if the labeling referred only to elevated hepatic enzymes                          |
| when           | (iv) Appropriate concurrent use exists  when there is credible evidence that the conditions for                                               |
| if             | for at least one use that is d if ferent from all the other active ingredients or                                                             |
| if             | for at least one use that is d if ferent from all other active ingredients or animal                                                          |
| if             | the conference, a list of proposed indications and, if available, a copy of the proposed labeling for                                         |
| until          | to postpone part or all of the meeting until  sufficient materials are provided to FDA.                                                       |
| if             | FDA and the potential applicant on the issue. if                                                                                              |
| when           | relating to a new animal drug to FDA. when                                                                                                    |
| if             | presubmission conference agreement will no longer be valid if : (i) The potential applicant makes to FDA,                                     |
| when           | Cosmetic Act (the act) apply to those terms when  used in this part.                                                                          |
| subject to     | to a drug under an application that is subject to a validity assessment because of significant questions regarding                            |
| if             | of a supplement for public health reasons or if a delay in making the change described in                                                     |
| if not         | Any such protocols,  if not included in the approved application, or changes to                                                               |
| if             | The supplement,  if  approved, may subsequently just                                                                                          |
| if             | not distribute the drug made using the change if within 30 days following FDA's receipt of the                                                |
| until          | not distribute the drug made using the change until the supplement has been amended to provide the                                            |
| if             | of the drug(s) made with the manufacturing change. if                                                                                         |
| if             | not contrary to such approved or permitted labeling. if                                                                                       |
| if             | and/or adulterated under section 501 of the act. if                                                                                           |
| if             | drug application or abbreviated new animal drug application if  the conditions described under &#167;&#8201;514.80(b)(5)(iii) are met.        |
| if             | forth in part 58 of this chapter, or, if the study was not conducted in compliance with                                                       |
| unless         | Drug Administration before the application has been approved, unless  it has been previously disclosed or acknowledged.                       |
| if             | the NADA file is available for public disclosure. if                                                                                          |
| if             | are appropriate for public consideration of a spec if ic pending issue, i.e., at an open session                                              |
| unless         | NADA file are immediately available for public disclosure unless extraordinary circumstances are shown: (1) All safety and                    |
| when           | following two alternative ways shall be publicly released when  the application is approved.                                                  |
| where          | data and information, which will be reviewed and, where  appropriate, revised by the Center.                                                  |
| unless         | (3) A protocol for a test or study,  unless it is shown to fall within the exemption                                                          |
| unless         | (6) An assay method or other analytical method,  unless it serves no regulatory or compliance purpose and                                     |
| unless         | time any one of the following events occurs unless extraordinary circumstances are known: (1) The NADA has                                    |
| unless         | NADA file are not available for public disclosure unless they have been previously disclosed to the public                                    |
| unless         | be disclosed by the Food and Drug Administration unless  it has previously been publicly disclosed or acknowledged.                           |
| if             | product, available to the applicant from any source if such information is pertinent to an evaluation of                                      |
| when           | identity, strength, quality, or purity of the drug, when such omission would bias an evaluation of the                                        |
| if             | implementation) must be included with the labeling or if there have been no changes, a statement of                                           |
| if             | of reports of adverse drug experiences to determine if there has been an increased frequency of serious                                       |
| if             | in the distribution or dispensing of prescription products if  the product is a prescription new animal drug.                                 |
| when           | the applicant must do the following: (1) State when a report applies to multiple applications and identify                                    |
| when           | establishment inspection is required to verify their adequacy. when                                                                           |
| until          | day after the mailing date of the request until  all of the requested samples are received.                                                   |
| if             | animal drug is safe or effective in use if it fails to include (among other things) a                                                         |
| when           | animal drug is safe and effective for use when there is a refusal or failure upon written                                                     |
| when           | may be informed that such application is approvable when satisfactory final printed labeling identical in content to                          |
| when           | the opportunity for hearing as prescribed by &#167;&#8201;514.111. when                                                                       |
| unless         | letter citing the inadequacies contained in the application, unless within 30 days the sponsor chooses to avail                               |
| if             | metabolites in edible products of food-producing animals; and, if such new animal drug is intended for use                                    |
| if             | with procedures set forth in &#167;&#8201;514.105(a)(1) and (2) if he/she determines that the application satisfies the requirements          |
| subject to     | (7) The new animal drug is a drug  subject to licensing under the animal virus, serum, and toxin                                              |
| if             | forth in part 58 of this chapter, or, if the study was not conducted in compliance with                                                       |
| subject to     | information to establish that the requested action is subject to categorical exclusion under &#167;&#8201;25.30 or &#167;&#8201;25.33 of this |
| if             | acceptable for filing, the applicant shall be not if ied within 30 days of receipt of the                                                     |
| if             | be filed as of the day originally received. if                                                                                                |
| if             | a proposal to refuse to approve the application, if the Commissioner determines upon the basis of the                                         |
| if             | or other restrictions for use of such drug if any tolerance or withdrawal period or other restrictions                                        |
| when           | any particular; or (8) Such drug induces cancer when ingested by man or animal or, after appropriate                                          |
| if             | shall not apply with respect to such drug if the Commissioner finds that, under the conditions of                                             |
| subject to     | information to establish that the requested action is subject to categorical exclusion under &#167;&#8201;25.30 or &#167;&#8201;25.33 of this |
| if             | no reason for the noncompliance is provided or, if  it is, the d                                                                              |
| unless         | the question of whether such application is approvable, unless by the 30th day following the date of                                          |
| if             | (b) The Commissioner shall not if y in writing the person holding an application                                                              |
| unless         | beyond the variations provided for in the application unless he has supplemented the application by filing with                               |
| unless         | beyond the variations provided for in the application unless he has supplemented the application by filing with                               |
| until          | such application or not available to the Secretary until after such application was approved, or tests by                                     |
| when           | or tests by methods not deemed reasonably applicable when such application was approved, evaluated together with the                          |
| when           | or tests by methods not deemed reasonably applicable when such application was approved, evaluated together with the                          |
| when           | or tests by methods not deemed reasonably applicable when such application was approved, evaluated together with the                          |
| if             | no reason for the noncompliance is provided or, if  it is, the d                                                                              |
| if             | (c) The Commissioner may not if y in writing the person holding an application                                                                |
| when           | him evaluated together with the evidence before him when the application was approved, the methods used in,                                   |
| when           | him evaluated together with the evidence before him when the application was approved, the methods used in,                                   |
| subject to     | drug application on the grounds that the drug subject to such application is no longer being marketed and                                     |
| if             | formulation and physical characterization (including delivery systems thereof, if any) of the new animal drug as presented                    |
| when           | The use of this control may be appropriate  when objective measurements of effectiveness, not subject to observer                             |
| not subject to | may be appropriate when objective measurements of effectiveness, not subject to  observer bias, are available.                                |
| when           | The use of this control is appropriate  when the use of a placebo control or of                                                               |
| when           | is accounted for by an appropriate design, and when , within the same animal, effects due to                                                  |
| when           | describe the criteria used to assess response, and, when appropriate, justify the selection of the methods to                                 |
| if             | the conditions under which the new animal drug, if  approved, is intended to be applied or administered.                                      |
| if             | to set forth clearly and concisely the spec if ic criteria from which waiver is sought, why                                                   |
| if             | of an applicant stating reasonable grounds therefor and if he finds that the facts so require, may                                            |
| if             | order denying or withdrawing approval of the application. if                                                                                  |
| if             | a hearing in accordance with &#167;&#167;&#8201;12.20 and 12.22. if                                                                           |
| if             | a hearing that a hearing is not just if ied because no genuine and substantial issue of                                                       |
| if             | for a hearing that a hearing is just if ied, the Commissioner will publish a notice setting                                                   |
| unless         | time period in which to request a hearing, unless the presiding officer and the applicant otherwise agree;                                    |
| as soon as     | of withdrawal of approval, the hearing will occur as soon as  practicable.                                                                    |
| if             | hearing will be open to the public; however, if the Commissioner finds that portions of the application                                       |
| unless         | hearing involving such portions will not be public, unless the respondent so specifies in the request for                                     |


## Entities

| Entities         | Context                                                                                                                                           |
|:-----------------|:--------------------------------------------------------------------------------------------------------------------------------------------------|
| Food             | Food  and Drugs.                                                                                                                                  |
| English          | in a foreign language, an accurate and complete English  translation shall be appended to such part.                                              |
| United States    | or have a place of business within the United States , the application must also furnish the name                                                 |
| United States    | or have a place of business within the United States , the application must also furnish the name                                                 |
| Chemical         | data in the following form: (i) Chemistry: (a) Chemical structural formula or description for any new animal                                      |
| Ingredient       | Ingredient labeling may utilize collective names as provided in                                                                                   |
| Reasonable       | Reasonable  variation may be specified.                                                                                                           |
| Similar          | Similar data may be required for Type B medicated                                                                                                 |
| Expiration       | Expiration dates shall be proposed for finished pharmaceutical dosage                                                                             |
| Appropriate      | Appropriate use of labeled compounds (e.g. radioactive tracers), may                                                                              |
| Drug             | Drug residue levels ordinarily should be determined in muscle,                                                                                    |
| Such             | Such information should include identification of the person who                                                                                  |
| United States    | investigations or commercial marketing (for example, outside the United States ), or reports in the scientific literature, both                   |
| Include          | Include any evaluation of the safety or effectiveness of                                                                                          |
| Explain          | (vii)  Explain any omission of reports from any investigator to                                                                                   |
| New              | (i)  New animal drugs as defined in &#167;&#8201;510.3 of this                                                                                    |
| Include          | Include in each application information applicable to the specific                                                                                |
| United States    | that information to the Attorney General of the United States .                                                                                   |
| Adverse          | Adverse drug experience is any adverse event associated with                                                                                      |
| Adverse          | Adverse drug experience includes, but is not limited to:                                                                                          |
| ANADA            | ANADA is an abbreviated new animal drug application including                                                                                     |
| Applicant        | Applicant is a person or entity who owns or                                                                                                       |
| Nonapplicant     | Nonapplicant is any person other than the applicant whose                                                                                         |
| Potential        | Potential applicant means any person: (1) Intending to investigate                                                                                |
| Serious          | Serious adverse drug experience is an adverse event that                                                                                          |
| Unexpected       | Unexpected adverse drug experience is an adverse event that                                                                                       |
| Adequate         | Adequate and well-controlled studies that are intended to provide                                                                                 |
| Such             | Such justification must be provided no later than 25                                                                                              |
| Dispute          | Dispute resolution procedures may be further explained by guidance                                                                                |
| Such             | Such withdrawal may be made without prejudice to a                                                                                                |
| United States    | made to a drug manufactured outside of the United States .                                                                                        |
| Untrue           | Untrue  statements in applications.                                                                                                               |
| Effectiveness    | FDA 1932 &#8220;Veterinary Adverse Drug Reaction, Lack of Effectiveness , Product Defect Report.&#8221; The mailing cover for                     |
| New Animal Drugs | &#8220;Transmittal of Periodic Reports and Promotional Materials for New Animal Drugs .&#8221; It must be submitted every 6 months                |
| Applicant        | Applicant and distributor current package labeling, including package inserts                                                                     |
| Review           | Review articles, papers, and abstracts in which the drug                                                                                          |
| Applicant        | Applicant must report adverse drug experiences and product/manufacturing defects                                                                  |
| Effectiveness    | FDA 1932, &#8220;Veterinary Adverse Drug Reaction, Lack of Effectiveness , Product Defect Report.&#8221; Periodic drug experience reports         |
| Periodic         | Drug Reaction, Lack of Effectiveness, Product Defect Report.&#8221; Periodic drug experience reports and special drug experience reports          |
| New Animal Drugs | &#8220;Transmittal of Periodic Reports and Promotional Material for New Animal Drugs ,&#8221; in accordance with directions provided on the       |
| Surveillance     | Internet at http://www.fda.gov/cvm/forms/forms.html, by telephoning the Division of Surveillance (HFV-210), or by submitting a written request to |
| Surveillance     | Internet at http://www.fda.gov/cvm/forms/forms.html, by telephoning the Division of Surveillance (HFV-210), or by submitting a written request to |
| Rockville, MD    | Medicine, Division of Surveillance (HFV-210), 7500 Standish Pl., Rockville, MD  20855-2764.                                                       |
| Rockville, MD    | Medicine, Document Control Unit (HFV-199), 7500 Standish Pl., Rockville, MD  20855-2764.                                                          |
| Annual           | Annual  reports for antimicrobial animal drug sales and distribution.                                                                             |
| United States    | number of units sold or distributed in the United States (i.e., domestic sales) for each month of the                                             |
| United States    | number of units sold or distributed outside the United States (i.e., quantities exported) for each month of the                                   |
| Evaluation       | Evaluation  and comment on applications.                                                                                                          |
| Approval         | Approval  of applications.                                                                                                                        |
| Approval         | Approval  of supplemental applications.                                                                                                           |
| English          | (1) It does not contain complete and accurate English translations of any pertinent part in a foreign                                             |
| United States    | or maintain a place of business within the United States and the application has not been countersigned by                                        |
| United States    | or maintain a place of business within the United States and the application has not been countersigned by                                        |
| Agriculture      | will be referred to the U.S. Department of Agriculture  for action.                                                                               |
| Refusal          | Refusal  to approve an application.                                                                                                               |
| New              | (ii)  New evidence not contained in such application or not                                                                                       |
| Adequate         | Adequate  and well-controlled studies.                                                                                                            |
| Adequate         | Adequate and well-controlled studies, in addition to providing a                                                                                  |
| Experimental     | Experimental units of animals are groups of animals that                                                                                          |
| Adequate         | Adequate and well-controlled field studies shall balance the need                                                                                 |
| Isolated         | Isolated case reports, random experience, and reports lacking the                                                                                 |
| Judicial         | Judicial  review.                                                                                                                                 |
| United States    | defined in &#167;&#8201;310.6 of this chapter, in a United States court of appeals pursuant to section 505(h) of                                  |


## Date

| Date       | Context                                                                                                                                                                                                                                                                                                                                                                        |
|:-----------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1975-07-01 | Such summaries shall consist of the following:                                                                                                                                                                                                                                                                                                                                 |
|            |               (i) For an NADA approved prior to July 1, 1975, internal agency records that describe such data and information, e.g., a summary of basis for approval or internal reviews of the data and information, after deletion of:                                                                                                                                       |
|            |               (a) Names and any information that would identify the investigators.                                                                                                                                                                                                                                                                                             |
| 1975-07-01 | (ii) For an NADA approved after July 1, 1975, a summary of such data and information prepared in one of the following two alternative ways shall be publicly released when the application is approved.                                                                                                                                                                        |
| 2018-01-01 | (2) Applicants must ensure that the beginning of the reporting period for the annual periodic drug experience reports for such applications is January 1.                                                                                                                                                                                                                      |
| 2018-01-01 | For applications that currently have a reporting period that begins on a date other than January 1, applicants must request a change in reporting submission date such that the reporting period begins on January 1 and ends on December 31, as described in paragraph (b)(4) of this section.                                                                                |
| 2018-01-01 | For applications that currently have a reporting period that begins on a date other than January 1, applicants must request a change in reporting submission date such that the reporting period begins on January 1 and ends on December 31, as described in paragraph (b)(4) of this section.                                                                                |
| 2018-12-31 | For applications that currently have a reporting period that begins on a date other than January 1, applicants must request a change in reporting submission date such that the reporting period begins on January 1 and ends on December 31, as described in paragraph (b)(4) of this section.                                                                                |
| 2301-05-01 | Form FDA 1932 and Form FDA 2301 may be obtained on the Internet at http://www.fda.gov/cvm/forms/forms.html, by telephoning the Division of Surveillance (HFV-210), or by submitting a written request to the following address: Food and Drug Administration, Center for Veterinary Medicine, Division of Surveillance (HFV-210), 7500 Standish Pl., Rockville, MD 20855-2764. |
| 2018-03-31 | (d) Each report must:                                                                                                                                                                                                                                                                                                                                                          |
|            |               (1) Be submitted not later than March 31 each year;                                                                                                                                                                                                                                                                                                              |
|            |               (2) Cover the period of the preceding calendar year; and                                                                                                                                                                                                                                                                                                         |
|            |               (3) Be submitted using Form FDA 3744, &#8220;Antimicrobial Animal Drug Distribution Report.&#8221;                                                                                                                                                                                                                                                               |
| 2018-12-31 | (f) FDA will publish an annual summary report of the data and information it receives under this section for each calendar year by December 31 of the following year.                                                                                                                                                                                                          |
| 1913-03-04 | (7) The new animal drug is a drug subject to licensing under the animal virus, serum, and toxin law of March 4, 1913 (37 Stat.                                                                                                                                                                                                                                                 |


